167,543 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Purchased by Soleus Capital Management L.P.

Soleus Capital Management L.P. bought a new position in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 167,543 shares of the company's stock, valued at approximately $7,241,000. Soleus Capital Management L.P. owned about 0.18% of Scholar Rock at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Global Retirement Partners LLC increased its position in shares of Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after acquiring an additional 766 shares during the period. Nisa Investment Advisors LLC grew its stake in Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after purchasing an additional 1,031 shares in the last quarter. Amalgamated Bank grew its stake in Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after purchasing an additional 620 shares in the last quarter. KBC Group NV purchased a new position in Scholar Rock during the 4th quarter worth $131,000. Finally, NEOS Investment Management LLC bought a new stake in Scholar Rock during the 4th quarter valued at $209,000. 91.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Wedbush reiterated an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a report on Wednesday, May 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Scholar Rock presently has an average rating of "Buy" and an average price target of $42.67.

Insider Transactions at Scholar Rock

In other news, insider Tracey Sacco sold 6,500 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $33.08, for a total transaction of $215,020.00. Following the transaction, the insider now owns 71,750 shares in the company, valued at $2,373,490. This represents a 8.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Edward H. Myles sold 142,292 shares of Scholar Rock stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the completion of the sale, the chief financial officer now owns 111,345 shares of the company's stock, valued at $3,966,108.90. This trade represents a 56.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 154,798 shares of company stock valued at $5,482,238 in the last quarter. 13.30% of the stock is currently owned by corporate insiders.

Scholar Rock Stock Down 0.8%

Shares of NASDAQ:SRRK traded down $0.26 on Thursday, reaching $30.46. The company had a trading volume of 673,145 shares, compared to its average volume of 1,268,433. The firm has a market capitalization of $2.89 billion, a PE ratio of -12.96 and a beta of 0.37. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98. The firm's 50 day simple moving average is $30.93 and its 200-day simple moving average is $35.91.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the firm earned ($0.59) EPS. As a group, analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.